Luckily there is an easy solution to this minor inconvenience: Yes, I'm talking about a butter crock. Better still, an ...

Rock and Roll Hall of Fame fan voting results revealed as singer demands more, more, more Live Updates: Massive NJ wildfire ...

Merck expects $200 million in added tariff costs, primarily impacting gross margins. The company has invested $12 billion since 2017, with another $9 billion planned to expand U.S. manufacturing ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US and China. The estimate doesn’t account for the possibility that ...

Merck KGaA is edging closer to the SpringWorks deal, which was first rumoured in February, confirming late-stage negotiations at an estimated price of $47 per share – potentially valuing the ...

Merck (MRK) lowers its 2025 profit outlook as the drugmaker expects a $200 million tariff hit. Nokia (NOK) warns of an earnings hit from tariffs in the second quarter after the company's first ...

Merck & Co. cut its 2025 earnings outlook, partly to account for recently imposed tariffs that it projects will total $200 million. The projection comes in light of the tariffs implemented so ...

Reacting to press speculation, Merck KGaA has acknowledged that talks to buy US biotech SpringWorks are now in the late stages and are revolving around an offer of around $47 per share.

Announcing better-than-expected financials for Q1 2025 on Thursday, Merck (NYSE:MRK) lowered its full-year outlook for earnings to account for various headwinds, including a $200M impact related ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement may come as soon as Monday, the people said, asking not to be ...

Halozyme Therapeutics (NASDAQ:HALO) on Thursday announced a lawsuit against Merck (NYSE:MRK) over allegations that an injectable version of the New Jersey-based pharma giant’s blockbuster cancer ...

Halozyme Therapeutics is suing Merck for patent infringement. The San Diego biotechnology company said Thursday it believes a proposed form of Merck's cancer medicine Keytruda uses a formulation ...